Track record · closed signal

Elanco Animal Health Incorporated (ELAN) — closed signal from September 24, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on December 23, 2025.

Predicted vs. what happened

ELAN price · publication thesis → realized outcomesplit-adjusted
$19.08 Published $23.84 Target $22.22 Window close $23.70 Peak
$18.60 – $19.20Entry zone — fair-value band
$19.08Published — price the day we called it
$23.84Target — the price the thesis aimed for
$23.70Peak — highest point inside the window, not a realized return
$22.22Window close — end-of-window price, context only

What happened

Target reached

Hit or exceeded the predicted growth inside the window.

Peak price
$23.70
peak on November 26, 2025 — not a realized return
Peak gain
+24.2%
peak, from the publication price
Window close
$22.22
end-of-window price, context only
Days to target
Window
September 24, 2025 – December 23, 2025

The thesis — published September 24, 2025

Predicted growth
+25%
over the measurement window
Target price
$23.84
the price the thesis aimed for
Entry zone
$18.60 – $19.20
the fair-value band we waited for
Price at publication
$19.08
published September 24, 2025
Confidence
62%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Elanco's near-term story is driven by fresh news. Being added to the S&P MidCap 400 can trigger automatic buying from investment funds, and the FDA removed a vaccine risk warning from Zenrelia, easing concern around a key product. The stock has fallen but is starting to stabilize. Over the next 0-3 months we expect a rebound from these forces, but we would stay disciplined if momentum fades. This is a short-term view while fundamentals improve.

Primary drivers

  • Joining the S&P MidCap 400 can spark automatic fund buying demand
  • FDA removed a warning on Zenrelia, easing safety worries for this key product
  • Shares fell hard but are starting to stabilize and recover in recent trading
  • Business results trail the stock move, so this stays a short-term idea

How it played out

ELAN: target was not reached after a 24.2% peak

Lyra published ELAN at 19.08 on 2025-09-24 as a short-term rebound idea. The thesis expected 25% growth over 0-3 months. It pointed to S&P MidCap 400 inclusion, the FDA removing a Zenrelia vaccine risk warning, recent stabilization after a hard fall, and still-lagging business results.

Inside the window, ELAN rose to 23.7 on 2025-11-26, a 24.2% peak gain. The target was 23.84, so it stayed below the target. It never got there. By 2025-12-23, the stock ended at 22.22. The thesis mostly played out on direction and size, but it missed the published target.

What happened during the window

On 2025-12-09, Investor's Business Daily reported that Elanco had reiterated its fourth-quarter and 2025 guidance at its investor day. The same report said third-quarter revenue rose 10%.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.